PMID- 33210737
OWN - NLM
STAT- MEDLINE
DCOM- 20211206
LR  - 20211214
IS  - 1365-2362 (Electronic)
IS  - 0014-2972 (Linking)
VI  - 51
IP  - 5
DP  - 2021 May
TI  - Paraoxonase-2: A potential biomarker for skin cancer aggressiveness.
PG  - e13452
LID - 10.1111/eci.13452 [doi]
AB  - BACKGROUND: Cutaneous neoplasms include melanoma and non-melanoma skin cancers 
      (NMSCs). Among NMSCs, basal cell carcinoma (BCC) represents the most common 
      lesion. On the contrary, although accounting for less than 5% of all skin 
      cancers, melanoma is responsible for most of cutaneous malignancy-related deaths. 
      Paraoxonase-2 (PON2) is an intracellular enzyme exerting a protective role 
      against production of reactive oxygen species within mitochondrial respiratory 
      chain. Recently, a growing attention has been focused on exploring the role of 
      PON2 in cancer. The aim of this study was to investigate the diagnostic and 
      prognostic role of PON2 in skin neoplasms. MATERIALS AND METHODS: 36 cases of 
      BCC, distinguished between nodular and infiltrative lesions, as well as 29 
      melanoma samples were analysed by immunohistochemistry to evaluate PON2 protein 
      expression. Subsequent statistical analyses were carried out to explore the 
      existence of correlations between intratumour enzyme levels and 
      clinicopathological features. RESULTS: Results obtained showed PON2 
      overexpression in BCCs compared with controls. In particular, distinguishing 
      between less and more aggressive tumour forms, we found no significant 
      differences in enzyme levels between nodular BCCs and controls. Conversely, PON2 
      expression was significantly higher in infiltrative BCCs compared with controls. 
      Moreover, the enzyme was strongly upregulated in melanoma samples with respect to 
      controls. Interestingly, PON2 levels were positively correlated with Breslow 
      thickness, Clark level, regression, mitoses, lymph node metastases, primary 
      tumour (pT) parameter and pathological stage. CONCLUSIONS: Reported findings seem 
      to suggest that PON2 expression levels could be positively related with tumour 
      aggressiveness of both BCC and melanoma.
CI  - (c) 2020 Stichting European Society for Clinical Investigation Journal Foundation. 
      Published by John Wiley & Sons Ltd.
FAU - Bacchetti, Tiziana
AU  - Bacchetti T
AD  - Department of Life and Environmental Sciences, Polytechnic University of Marche, 
      Ancona, Italy.
FAU - Salvolini, Eleonora
AU  - Salvolini E
AD  - Department of Clinical Sciences, Polytechnic University of Marche, Ancona, Italy.
FAU - Pompei, Veronica
AU  - Pompei V
AD  - Department of Clinical Sciences, Polytechnic University of Marche, Ancona, Italy.
FAU - Campagna, Roberto
AU  - Campagna R
AD  - Department of Clinical Sciences, Polytechnic University of Marche, Ancona, Italy.
FAU - Molinelli, Elisa
AU  - Molinelli E
AD  - Department of Clinical and Molecular Sciences, Polytechnic University of Marche, 
      Ancona, Italy.
FAU - Brisigotti, Valerio
AU  - Brisigotti V
AD  - Department of Clinical and Molecular Sciences, Polytechnic University of Marche, 
      Ancona, Italy.
FAU - Togni, Lucrezia
AU  - Togni L
AD  - Department of Clinical Sciences, Polytechnic University of Marche, Ancona, Italy.
FAU - Lucarini, Guendalina
AU  - Lucarini G
AUID- ORCID: 0000-0003-3218-5620
AD  - Department of Clinical and Molecular Sciences, Polytechnic University of Marche, 
      Ancona, Italy.
FAU - Sartini, Davide
AU  - Sartini D
AUID- ORCID: 0000-0003-3879-8647
AD  - Department of Clinical Sciences, Polytechnic University of Marche, Ancona, Italy.
FAU - Campanati, Anna
AU  - Campanati A
AD  - Department of Clinical and Molecular Sciences, Polytechnic University of Marche, 
      Ancona, Italy.
FAU - Mattioli-Belmonte, Monica
AU  - Mattioli-Belmonte M
AD  - Department of Clinical and Molecular Sciences, Polytechnic University of Marche, 
      Ancona, Italy.
FAU - Rubini, Corrado
AU  - Rubini C
AD  - Department of Biomedical Sciences and Public Health, Polytechnic University of 
      Marche, Ancona, Italy.
FAU - Ferretti, Gianna
AU  - Ferretti G
AD  - Department of Clinical Sciences, Polytechnic University of Marche, Ancona, Italy.
FAU - Offidani, Annamaria
AU  - Offidani A
AD  - Department of Clinical and Molecular Sciences, Polytechnic University of Marche, 
      Ancona, Italy.
FAU - Emanuelli, Monica
AU  - Emanuelli M
AD  - Department of Clinical Sciences, Polytechnic University of Marche, Ancona, Italy.
AD  - New York-Marche Structural Biology Center (NY-MaSBiC), Polytechnic University of 
      Marche, Ancona, Italy.
LA  - eng
PT  - Journal Article
DEP - 20201201
PL  - England
TA  - Eur J Clin Invest
JT  - European journal of clinical investigation
JID - 0245331
RN  - EC 3.1.8.1 (Aryldialkylphosphatase)
RN  - EC 3.1.8.1 (PON2 protein, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aryldialkylphosphatase/*metabolism
MH  - Carcinoma, Basal Cell/*metabolism/pathology
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - Lymph Nodes/pathology
MH  - Male
MH  - Melanoma/*metabolism/pathology
MH  - Middle Aged
MH  - Mitotic Index
MH  - Neoplasm Invasiveness
MH  - Skin Neoplasms/*metabolism/pathology
MH  - Tumor Burden
OTO - NOTNLM
OT  - basal cell carcinoma
OT  - immunohistochemistry
OT  - melanoma
OT  - paraoxonase-2
OT  - skin cancers
OT  - tumour biomarker
EDAT- 2020/11/20 06:00
MHDA- 2021/12/15 06:00
CRDT- 2020/11/19 08:47
PHST- 2020/11/04 00:00 [revised]
PHST- 2020/09/03 00:00 [received]
PHST- 2020/11/05 00:00 [accepted]
PHST- 2020/11/20 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2020/11/19 08:47 [entrez]
AID - 10.1111/eci.13452 [doi]
PST - ppublish
SO  - Eur J Clin Invest. 2021 May;51(5):e13452. doi: 10.1111/eci.13452. Epub 2020 Dec 
      1.